Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Biolase Stock (NASDAQ: BIOL) stock price, news, charts, stock research, profile.
Open1.820 | Close1.860 |
Vol / Avg.167.604K / 313.932K | Mkt Cap1.910M |
Day Range1.700 - 1.910 | 52 Wk Range1.560 - 268.000 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.850 | (EXPECTED) 2023-11-09 | |||||
REV | 13.960M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -5.330 | -4.240 | 1.0900 | ||||
REV | 15.360M | 14.286M | -1.074M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-05-31 | Lake Street | Frank Takkinen | Maintains | BuyBuy | Lowers | 1.50 | 0.40 |
2023-03-29 | Maxim Group | Anthony Vendetti | Maintains | Buy | Lowers | 5.00 | 1.00 |
2023-03-29 | Benchmark | Bruce Jackson | Reiterates | Speculative Buy | Maintains | - | 2.00 |
2023-01-20 | Lake Street | Frank Takkinen | Assumes | Buy | Announces | - | 1.50 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIOL | Biolase | 1.67% | 1.9M |
VTAK | Catheter Precision | -1.27% | 2.9M |
NXL | Nexalin Technology | -12.94% | 3.1M |
MOTS | Motus GI Hldgs | 0% | 2.7M |
TIVC | Tivic Health Systems | -3.35% | 2.5M |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Catheter Precision (AMEX:VTAK), Nexalin Technology (NASDAQ:NXL), Motus GI Hldgs (NASDAQ:MOTS), Tivic Health Systems (NASDAQ:TIVC) and Reshape Lifesciences (NASDAQ:RSLS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to fall to within 12 months (a possible -78.14% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $1.83 last updated Today at September 29, 2023 at 11:26 PM UTC.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.